Thinking outside the box about COX-1 in Alzheimer's disease

Neurobiology of Disease

Volumn 38, Issue 3, 2010, Pages 492-494

  Frautschy, Sally A ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

COX 1; COX 2; MCI; NSAIDs; Tg2576

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-42]; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; IBUPROFEN; INDOMETACIN; NAPROXEN; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; ROFECOXIB; TRIFLUSAL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINAL BLEEDING; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; COGNITION DISORDERS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE PROTEINS; MICE; SALICYLATES;

EID: 77952554514     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.02.009     Document Type: Note

References (35)

1. Agdeppa E.D., et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 2002, 117:723-730.
2. Aisen P.S., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54:588-593.
3. Aisen P.S., et al. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res. 2008, 5:73-82.
4. Akiyama H., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
5. Choi, J.K., et al., 2009. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. PMID 19679126. doi:10.1016/j.expneurol.2009.07.032.
6. Coma, M., et al., 2010. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. (Electronic publication ahead of print). PMID: 20149872. doi:10.1016/j.nbd.2010.01.019.
7. Gomez-Isla T., et al. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis. Assoc. Disord. 2008, 22:21-29.
8. Heneka M.T., et al. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 2005, 128:1442-1453.
9. Hoozemans J.J., et al. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des. 2008, 14:1419-1427.
10. Ikonomovic M.D., et al. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J. Histochem. Cytochem. 2008, 56:1065-1073.
11. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
12. Jantzen P.T., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 2002, 22:2246-2254.
13. Jespersen B., et al. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Nephrol. Dial. Transplant. 2009, 24:1644-1655.
14. Kotilinek L.A., et al. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 2008, 131:651-664.
15. Kukar T., et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007, 8:54.
16. Laino C. In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients with healthy brains. Neurol. Today 2009, 9:21-22.
17. Lim G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000, 20(15):5709-5714.
18. Lim G.P., et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 2001, 22:983-981.
19. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J. Alzheimers Dis. 2010, 19:355-361.
20. McKee A.C., et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
21. Morihara T., et al. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 2005, 30:1111-1120.
22. O'Banion M.K., et al. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J. Neurochem. 1996, 66:2532-2540.
23. Pepicelli O., et al. Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-d-aspartate receptors in rat hippocampus. J. Neurochem. 2005, 93:1561-1567.
24. Rall J.M., et al. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res. 2003, 968:273-276.
25. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 2008, 11:81s-110s.
26. Rogers J., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
27. Scharf S., et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999, 53:197-201.
28. Small G.W., et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am. J. Geriatr. Psychiatry 2008, 16:999-1009.
29. Streit W.J., et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:475-485.
30. Tanaka K., et al. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis. Eur. J. Pharmacol. 2009, 603:120-132.
31. Walker D.G., et al. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp. Neurol. 2009, 215:5-19.
32. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216.
33. Xiang Z., et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002, 10:271-278.
34. Yan Q., et al. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
35. Yao Y., et al. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann. Neurol. 2005, 58:623-626.